Prophylaxis Of Wound Infections- Antibiotics in Renal Donation

Are Prophylactic Antibiotics Necessary Before Laparoscopic Living Kidney Donation? A Double Blind, Randomised, Controlled Trial.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02089568

Acronym

POWAR

Enrollment

284

Registered

2014-03-18

Start date

2012-07-31

Completion date

2016-08-31

Last updated

2016-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Keywords

Living donation, Antibiotics, Laparoscopic surgery

Brief summary

The aim of this study is to see whether antibiotics given at the start of laparoscopic kidney donation surgery prevent infection.

Detailed description

Subjects undergoing laparoscopic donor nephrectomy will be randomised to either a single dose of intravenous co-amoxiclav or placebo prior to surgery. Outcome measures include any infections, length of stay and costs

Interventions

DRUGCo-Amoxiclav

Will receive 1.2g co-amoxiclav at induction

DRUGNormal Saline

Placebo - 0.9% saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All adult patients (over 18 years) undergoing hand-assisted laparoscopic donor nephrectomy, who have given written informed consent, will be included. * Patients whose first language is not English will be included; they comprise a significant part of our patient population and we will use translation services as is our normal practice. * Women of child-bearing age taking adequate contraception will be included.

Exclusion criteria

* Patients with a known allergy to penicillin or other antibiotics. * Patients with MRSA colonisation. * Participation in another investigational study within the previous 90 days. * Pregnant or breast-feeding women.

Design outcomes

Primary

Measure	Time frame
Rate of infection after surgery	24 months

Secondary

Measure	Time frame	Description
Length of hospital stay	24 months	—
Readmission rates	24 months	—
Antibiotic associated side effects	24 months	Including diarrhoea and allergic reactions
Ultrasonic evidence of wound healing	24 months	Wounds will be assessed using high resolution ultrasound to assess dermal and epidermal healing.
Quality of life	24 months	—
Relative costs	24 months	—
Return to work and normal activities	24 months	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026